litlas
Log inCreate account

John M. Goldman

Active 1974–2013

143
Papers
43,465
Citations
103
h-index
143
i10-index

Citations

Citations per year for John M. Goldman1975: 1 citations1976: 4 citations1977: 1 citations1978: 1 citations1979: 15 citations1980: 5 citations1981: 10 citations1982: 8 citations1983: 8 citations1984: 16 citations1985: 10 citations1986: 10 citations1987: 12 citations1988: 19 citations1989: 37 citations1990: 40 citations1991: 31 citations1992: 41 citations1993: 53 citations1994: 58 citations1995: 59 citations1996: 50 citations1997: 54 citations1998: 71 citations1999: 120 citations2000: 145 citations2001: 192 citations2002: 370 citations2003: 413 citations2004: 326 citations2005: 303 citations2006: 324 citations2007: 384 citations2008: 346 citations2009: 360 citations2010: 382 citations2011: 365 citations2012: 354 citations2013: 331 citations2014: 314 citations2015: 286 citations2016: 272 citations2017: 198 citations2018: 151 citations2019: 634 citations2020: 521 citations2021: 423 citations2022: 335 citations2023: 164 citations2024: 337 citations2025: 114 citations2026: 2 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,867 citing papers, 30.2% of this breakdownUnited Kingdom: 841 citing papers, 8.9% of this breakdownGermany: 702 citing papers, 7.4% of this breakdownItaly: 570 citing papers, 6% of this breakdownFrance: 526 citing papers, 5.6% of this breakdownChina: 387 citing papers, 4.1% of this breakdownAustralia: 302 citing papers, 3.2% of this breakdownCanada: 279 citing papers, 2.9% of this breakdownSwitzerland: 269 citing papers, 2.8% of this breakdownJapan: 265 citing papers, 2.8% of this breakdownNetherlands: 256 citing papers, 2.7% of this breakdownSpain: 226 citing papers, 2.4% of this breakdown
0%30.2%Other 21%

Institutions

Fields

  • Medicine74.9%
  • Biochemistry, Genetics and Molecular Biology16.8%
  • Immunology and Microbiology4.3%
  • Computer Science0.7%
  • Mathematics0.5%
  • Chemistry0.5%
  • Other2.3%

Topics

  • Chronic Myeloid Leukemia Treatments13.1%
  • Chronic Lymphocytic Leukemia Research6.9%
  • Eosinophilic Disorders and Syndromes5.9%
  • Acute Myeloid Leukemia Research5.2%
  • Hematopoietic Stem Cell Transplantation4.8%
  • Acute Lymphoblastic Leukemia research3.2%
  • Other60.9%

Coauthors

All papers

Open in search
  1. A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Authors: Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz, Philipp le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, John F. DiPersio, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Réa, Michele Baccarani, Martin C. Müller, Carlo Gambacorti‐Passerini, Siu‐Fun Wong, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G. Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, John M. Goldman, Neil P. Shah, Hagop M. Kantarjian - New England Journal of Medicine 2013 cited by 1,124

  2. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

    Authors: Brian Druker, François Guilhot, Stephen G. O’Brien, Insa Gathmann, Hagop M. Kantarjian, Norbert Gattermann, Michael W. Deininger, Richard T. Silver, John M. Goldman, Richard M. Stone, Francisco Cervantes, Andreas Hochhaus, Bayard L. Powell, Janice Gabrilove, Philippe Rousselot, Josy Reiffers, Jan J. Cornelissen, Timothy P. Hughes, Hermine Agis, Thomas Fischer, Gregor Verhoef, John D. Shepherd, Giuseppe Saglio, Aloïs Gratwohl, Johan Lanng Nielsen, Jerald P. Radich, Bengt Simonsson, Kerry Taylor, Michele Baccarani, Charlene So, Laurie Letvak, Richard A. Larson - New England Journal of Medicine 2006 cited by 3,481

  3. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

    Authors: Stephen G. O’Brien, François Guilhot, Richard A. Larson, Insa Gathmann, Michele Baccarani, Francisco Cervantes, Jan J. Cornelissen, Thomas Fischer, Andreas Hochhaus, Timothy P. Hughes, Klaus Lechner, Johan Lanng Nielsen, Philippe Rousselot, Josy Reiffers, Giuseppe Saglio, John D. Shepherd, Bengt Simonsson, Aloïs Gratwohl, John M. Goldman, Hagop M. Kantarjian, Kerry Taylor, Gregor Verhoef, Ann E. Bolton, Renaud Capdeville, Brian Druker - New England Journal of Medicine 2003 cited by 3,565

  4. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Authors: Michele Baccarani, Michael Deininger, Gianantonio Rosti, Andreas Hochhaus, Simona Soverini, Jane F. Apperley, Francisco Cervantes, Richard E. Clark, Jörge E. Cortes, François Guilhot, Henrik Hjorth‐Hansen, Timothy P. Hughes, Hagop M. Kantarjian, Dong‐Wook Kim, Richard A. Larson, Jeffrey H. Lipton, François-Xavier Mahon, Giovanni Martinelli, Jiřı́ Mayer, Martin Müller, Dietger Niederwieser, Fabrizio Pane, Jerald P. Radich, Philippe Rousselot, Giuseppe Saglio, Susanne Saußele, Charles A. Schiffer, Richard T. Silver, Bengt Simonsson, Juan-Luis Steegmann, John M. Goldman, Rüdiger Hehlmann - Blood 2013 cited by 1,989

  5. The molecular biology of chronic myeloid leukemia

    Authors: Michael W. Deininger, John M. Goldman, Junia V. Melo - Blood 2000 cited by 1,620

  6. Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation

    Authors: Aristeidis Chaidos, Scott D. Patterson, Richard Szydlo, Mohammed S. Chaudhry, Francesco Dazzi, Edward Kanfer, Donald M. McDonald, David Marin, Dragana Milojković, Jiří Pavlů, John Davis, Amin Rahemtulla, Katy Rezvani, John M. Goldman, Irene Roberts, Jane F. Apperley, Anastasios Karadimitris - Blood 2012 cited by 162

  7. Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

    Authors: David Marín, Alexandra Bazeos, François-Xavier Mahon, Lina Eliasson, Dragana Milojković, Marco Bua, Jane F. Apperley, Richard Szydlo, Ritti Desai, Kasia Kozlowski, Christos Paliompeis, Victoria Latham, Letizia Foroni, Mathiéu Molimard, Alistair Reid, Katy Rezvani, Hugues de Lavallade, Cristina Guallar, John M. Goldman, Jamshid S. Khorashad - Journal of Clinical Oncology 2010 cited by 901

  8. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

    Authors: Michele Baccarani, Jörge E. Cortes, Fabrizio Pane, Dietger Niederwieser, Giuseppe Saglio, Jane F. Apperley, Francisco Cervantes, Michael W. Deininger, Aloïs Gratwohl, François Guilhot, Andreas Hochhaus, Mary M. Horowitz, Timothy P. Hughes, Hagop M. Kantarjian, Richard A. Larson, Jerald P. Radich, Bengt Simonsson, Richard T. Silver, John M. Goldman, Rüdiger Hehlmann - Journal of Clinical Oncology 2009 cited by 1,298

  9. Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia

    Authors: Timothy P. Hughes, Jaspal Kaeda, Susan Branford, Zbigniew Rudzki, Andreas Hochhaus, Martee L. Hensley, Insa Gathmann, Ann E. Bolton, Iris C. van Hoomissen, John M. Goldman, Jerald P. Radich - New England Journal of Medicine 2003 cited by 1,222

  10. Regulation of myeloid leukaemia by the cell-fate determinant Musashi

    Authors: Takahiro Ito, Hyog Young Kwon, Bryan Zimdahl, Kendra L. Congdon, Jordan Blum, William Lento, Chen Zhao, Anand S. Lagoo, Gareth Gerrard, Letizia Foroni, John M. Goldman, Harriet Goh, Soo Hyun Kim, Dong‐Wook Kim, Charles Chuah, Vivian G. Oehler, Jerald P. Radich, Craig T. Jordan, Tannishtha Reya - Nature 2010 cited by 366

  11. Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

    Authors: Hugues de Lavallade, Jane F. Apperley, Jamshid S. Khorashad, Dragana Milojković, Alistair Reid, Marco Bua, Richard Szydlo, Eduardo Olavarría, Jaspal Kaeda, John M. Goldman, David Marín - Journal of Clinical Oncology 2008 cited by 556

  12. Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

    Authors: David Marín, Amr R. Ibrahim, Claire Lucas, Gareth Gerrard, Lihui Wang, Richard Szydlo, Richard E. Clark, Jane F. Apperley, Dragana Milojković, Marco Bua, Jiří Pavlů, Christos Paliompeis, Alistair Reid, Katayoun Rezvani, John M. Goldman, Letizia Foroni - Journal of Clinical Oncology 2011 cited by 475

  13. Reorganizing patient care and workflow in the operating room: a cost-effectiveness study

    Authors: J.‐P. Stahl, Warren S. Sandberg, Bethany Daily, Richard A. Wiklund, M.F. Egan, John M. Goldman, Keith Isaacson, Scott Gazelle, David W. Rattner - Surgery 2006 cited by 140

  14. Hematology: basic principles and practice

    Authors: John M. Goldman - Bone Marrow Transplantation 2013 cited by 497

  15. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

    Authors: Timothy P. Hughes, Andreas Hochhaus, Susan Branford, Martin C. Müller, Jaspal Kaeda, Letizia Foroni, Brian Druker, François Guilhot, Richard A. Larson, Stephen G. O’Brien, Marc S. Rudoltz, Manisha Mone, Elisabeth Wehrle, Vijay Modur, John M. Goldman, Jerald P. Radich, on behalf of the IRIS investigators - Blood 2010 cited by 487

  16. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA–peptide tetramers

    Authors: Mark Cobbold, Naeem Khan, Batoul Pourgheysari, Sudhir Tauro, Dorothy McDonald, Husam Osman, Mario Assenmacher, Lucinda Billingham, Colin G. Steward, Charles Crawley, Eduardo Olavarría, John M. Goldman, Ronjon Chakraverty, Premini Mahendra, Charles Craddock, Paul Moss - The Journal of Experimental Medicine 2005 cited by 477

  17. Chronic myeloid leukemia: mechanisms of blastic transformation

    Authors: Danilo Perrotti, Catriona Jamieson, John M. Goldman, Tomasz Skórski - Journal of Clinical Investigation 2010 cited by 395

  18. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

    Authors: Amr R. Ibrahim, Lina Eliasson, Jane F. Apperley, Dragana Milojković, Marco Bua, Richard Szydlo, François‐Xavier Mahon, Kasia Kozlowski, Christos Paliompeis, Letizia Foroni, Jamshid S. Khorashad, A. Bazeos, Mathiéu Molimard, Alistair Reid, Katayoun Rezvani, Gareth Gerrard, John M. Goldman, David Marín - Blood 2011 cited by 316

  19. Identical-Twin Bone Marrow Transplants for Leukemia

    Authors: Robert Peter Gale, Mary M. Horowitz, Robert C. Ash, Richard E. Champlin, John M. Goldman, Alfred A. Rimm, Olle Ringden, Judith A. Veum Stone, Mortimer M. Bortin - Annals of Internal Medicine 1994 cited by 288

  20. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

    Authors: Paolo Neviani, Jason G. Harb, Joshua J. Oaks, Ramasamy Santhanam, Christopher J. Walker, Justin J. Ellis, Gregory Ferenchak, Adrienne M. Dorrance, Carolyn Paisie, Anna M. Eiring, Yihui Ma, Hsiaoyin Mao, Bin Zhang, Mark Wunderlich, Philippa C. May, Chaode Sun, Sahar A. Saddoughi, Jacek Bielawski, William Blum, Rebecca B. Klisovic, Janelle A. Solt, John C. Byrd, Stefano Volinia, Jörge E. Cortes, Claudia S. Huettner, Steffen Koschmieder, Tessa L. Holyoake, Steven M. Devine, Michael A. Caligiuri, Carlo M. Croce, Ramiro Garzon, Besim Öğretmen, Ralph B. Arlinghaus, Ching-Shih Chen, Robert Bittman, Peter Hokland, Denis-Claude Roy, Dragana Milojković, Jane F. Apperley, John M. Goldman, Alistair Reid, James C. Mulloy, Ravi Bhatia, Guido Marcucci, Danilo Perrotti - Journal of Clinical Investigation 2013 cited by 219

  21. Durable responses to imatinib in patients with PDGFRB fusion gene–positive and BCR-ABL–negative chronic myeloproliferative disorders

    Authors: Marianna Dávid, Nicholas C.P. Cross, Sonja Burgstaller, Andrew Chase, Claire Curtis, Raymond Dang, Martine Gardembas, John M. Goldman, Francis Grand, George S. Hughes, Françoise Huguet, Louise Lavender, Grant A. McArthur, François Xavier Mahon, Giorgio Massimini, Junia V. Melo, Philippe Rousselot, R. Russell‐Jones, John F. Seymour, Graeme Smith, Alastair Stark, Katherine Waghorn, Zariana Nikolova, Jane F. Apperley - Blood 2006 cited by 173

  22. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

    Authors: Andreas Hochhaus, S G O'Brien, François Guilhot, Brian Druker, Susan Branford, Letizia Foroni, John M. Goldman, Martin Müller, Jerald P. Radich, Marc S. Rudoltz, Manisha Mone, Insa Gathmann, Timothy P. Hughes, Richard A. Larson, for the IRIS Investigators - Leukemia 2009 cited by 845

  23. Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta

    Authors: Jane F. Apperley, Martine Gardembas, Junia V. Melo, R. Russell‐Jones, Barbara J. Bain, E. Joanna Baxter, Andrew Chase, Judith M. Chessells, Marie Colombat, Claire Dearden, Saša Dimitrijević, François-X. Mahon, David Marin, Zariana Nikolova, Eduardo Olavarría, Sandra Silberman, Beate Schultheis, Nicholas C.P. Cross, John M. Goldman - New England Journal of Medicine 2002 cited by 631

  24. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

    Authors: François‐Xavier Mahon, Françis Belloc, Valérie Lagarde, Claudine Chollet, François Moreau‐Gaudry, Josy Reiffers, John M. Goldman, Junia V. Melo - Blood 2003 cited by 538